NANOBIOANÁLISIS
NBA

Ángel
Ramírez Payer
Publications by the researcher in collaboration with Ángel Ramírez Payer (15)
2023
-
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
Cancer Immunology, Immunotherapy, Vol. 72, Núm. 7, pp. 2529-2539
2021
2020
-
Driver mutations and single copy number abnormalities identify binet stage a patients with chronic lymphocytic leukemia with aggressive progression
Journal of Clinical Medicine, Vol. 9, Núm. 11, pp. 1-8
-
Expression of CD47 antigen in Reed–Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 782-785
-
Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 10
2019
-
The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
Frontiers in Immunology, Vol. 10
2018
-
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
Frontiers in immunology, Vol. 9, pp. 2917
2017
-
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia
OncoImmunology, Vol. 6, Núm. 10
2016
2015
-
On the prediction of Hodgkin lymphoma treatment response
Clinical and Translational Oncology, Vol. 17, Núm. 8, pp. 612-619
-
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy
Leukemia and Lymphoma, Vol. 56, Núm. 11, pp. 3096-3102
2014
-
Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia.Correlation with progressive disease
PLoS ONE, Vol. 9, Núm. 10
-
Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
BioMed Research International, Vol. 2014
2013
-
Lenalidomide and chronic lymphocytic leukemia
BioMed Research International, Vol. 2013